Australian Psychologist:精神健康状况可作为糖尿病自我监护指标

2013-04-23 晓东 编译 医学论坛网

  斯威本科技大学健康与社会研究中心学者Naomi Hackworth等人开展的一项研究提示,精神健康状况或可作为糖尿病自我监护指标。   研究者在城市与农村青年1型糖尿病患者中评估糖尿病自我护理(治疗依从性情况)、代谢控制(糖化血红蛋白水平)以及精神健康的心理社会性预测因子。入选的123例青少年/成年早期(平均年龄16岁)1型糖尿病患者(50例男性,73例女性)均完成一项调研问卷,报告其糖尿病

  斯威本科技大学健康与社会研究中心学者Naomi Hackworth等人开展的一项研究提示,精神健康状况或可作为糖尿病自我监护指标。

  研究者在城市与农村青年1型糖尿病患者中评估糖尿病自我护理(治疗依从性情况)、代谢控制(糖化血红蛋白水平)以及精神健康的心理社会性预测因子。入选的123例青少年/成年早期(平均年龄16岁)1型糖尿病患者(50例男性,73例女性)均完成一项调研问卷,报告其糖尿病自我护理、代谢控制与精神健康情况,有潜在风险的行为与态度,糖尿病自我效能、社区管理,以及感知到的社会支持。

  受试者各指标结果并无城乡差异。自我效能较高、风险行为较少,对风险行为态度保守的青少年,糖尿病自我监护结果更好,其结果预测代谢控制、精神健康状况指标结果更好。

  社会支持与社区医疗活动对糖尿病自我监护无影响。

糖尿病相关的拓展阅读:


Predictors of Diabetes Self-care, Metabolic Control, and Mental Health in Youth with Type 1 Diabetes
Abstract
The purpose of this study was to explore the psychosocial predictors of diabetes self-care (adherence to care regimes), metabolic control (glycated haemoglobin), and mental health among rural- and urban-dwelling youth with type 1 diabetes. One hundred and twenty three adolescents/young adults (aged 13−25 years, mean = 16 years, standard deviation = 3.8 years) with type 1 diabetes, 50 males and 73 females, completed questionnaires reporting on diabetes self-care, metabolic control, mental health (negative affect, quality of life), risk-taking behaviours and attitudes, diabetes self-efficacy, community engagement, and perceived social support. No rural/urban differences were detected on key predictors or outcome variables. Structural equation modelling revealed that high diabetes self-efficacy, lower risk behaviour, and more conservative attitudes to risk taking predicted better diabetes self-care, which in turn predicted better metabolic control and mental health. Social support and engagement in community activities did not influence diabetes self-care. The study has significance because both diabetes self-efficacy and propensity towards risk behaviour are potential targets for educational and counselling interventions designed to improve diabetes self-care regimes and resultant metabolic and mental health outcomes.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1678182, encodeId=d09416e818255, content=<a href='/topic/show?id=7f2c1e736f1' target=_blank style='color:#2F92EE;'>#TRALI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17736, encryptionId=7f2c1e736f1, topicName=TRALI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Mar 18 11:26:00 CST 2014, time=2014-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656574, encodeId=23dd16565e415, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri Jan 24 18:26:00 CST 2014, time=2014-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455096, encodeId=d338145509601, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Thu Apr 25 00:26:00 CST 2013, time=2013-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510967, encodeId=e909151096e79, content=<a href='/topic/show?id=5a822e867b5' target=_blank style='color:#2F92EE;'>#健康状况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27867, encryptionId=5a822e867b5, topicName=健康状况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e3710287449, createdName=kkunny, createdTime=Thu Apr 25 00:26:00 CST 2013, time=2013-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551081, encodeId=16be1551081b6, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Thu Apr 25 00:26:00 CST 2013, time=2013-04-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1678182, encodeId=d09416e818255, content=<a href='/topic/show?id=7f2c1e736f1' target=_blank style='color:#2F92EE;'>#TRALI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17736, encryptionId=7f2c1e736f1, topicName=TRALI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Mar 18 11:26:00 CST 2014, time=2014-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656574, encodeId=23dd16565e415, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri Jan 24 18:26:00 CST 2014, time=2014-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455096, encodeId=d338145509601, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Thu Apr 25 00:26:00 CST 2013, time=2013-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510967, encodeId=e909151096e79, content=<a href='/topic/show?id=5a822e867b5' target=_blank style='color:#2F92EE;'>#健康状况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27867, encryptionId=5a822e867b5, topicName=健康状况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e3710287449, createdName=kkunny, createdTime=Thu Apr 25 00:26:00 CST 2013, time=2013-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551081, encodeId=16be1551081b6, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Thu Apr 25 00:26:00 CST 2013, time=2013-04-25, status=1, ipAttribution=)]
    2014-01-24 bsmagic9140
  3. [GetPortalCommentsPageByObjectIdResponse(id=1678182, encodeId=d09416e818255, content=<a href='/topic/show?id=7f2c1e736f1' target=_blank style='color:#2F92EE;'>#TRALI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17736, encryptionId=7f2c1e736f1, topicName=TRALI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Mar 18 11:26:00 CST 2014, time=2014-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656574, encodeId=23dd16565e415, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri Jan 24 18:26:00 CST 2014, time=2014-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455096, encodeId=d338145509601, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Thu Apr 25 00:26:00 CST 2013, time=2013-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510967, encodeId=e909151096e79, content=<a href='/topic/show?id=5a822e867b5' target=_blank style='color:#2F92EE;'>#健康状况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27867, encryptionId=5a822e867b5, topicName=健康状况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e3710287449, createdName=kkunny, createdTime=Thu Apr 25 00:26:00 CST 2013, time=2013-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551081, encodeId=16be1551081b6, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Thu Apr 25 00:26:00 CST 2013, time=2013-04-25, status=1, ipAttribution=)]
    2013-04-25 july_977
  4. [GetPortalCommentsPageByObjectIdResponse(id=1678182, encodeId=d09416e818255, content=<a href='/topic/show?id=7f2c1e736f1' target=_blank style='color:#2F92EE;'>#TRALI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17736, encryptionId=7f2c1e736f1, topicName=TRALI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Mar 18 11:26:00 CST 2014, time=2014-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656574, encodeId=23dd16565e415, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri Jan 24 18:26:00 CST 2014, time=2014-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455096, encodeId=d338145509601, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Thu Apr 25 00:26:00 CST 2013, time=2013-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510967, encodeId=e909151096e79, content=<a href='/topic/show?id=5a822e867b5' target=_blank style='color:#2F92EE;'>#健康状况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27867, encryptionId=5a822e867b5, topicName=健康状况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e3710287449, createdName=kkunny, createdTime=Thu Apr 25 00:26:00 CST 2013, time=2013-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551081, encodeId=16be1551081b6, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Thu Apr 25 00:26:00 CST 2013, time=2013-04-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1678182, encodeId=d09416e818255, content=<a href='/topic/show?id=7f2c1e736f1' target=_blank style='color:#2F92EE;'>#TRALI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17736, encryptionId=7f2c1e736f1, topicName=TRALI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Mar 18 11:26:00 CST 2014, time=2014-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656574, encodeId=23dd16565e415, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri Jan 24 18:26:00 CST 2014, time=2014-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455096, encodeId=d338145509601, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Thu Apr 25 00:26:00 CST 2013, time=2013-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510967, encodeId=e909151096e79, content=<a href='/topic/show?id=5a822e867b5' target=_blank style='color:#2F92EE;'>#健康状况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27867, encryptionId=5a822e867b5, topicName=健康状况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e3710287449, createdName=kkunny, createdTime=Thu Apr 25 00:26:00 CST 2013, time=2013-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551081, encodeId=16be1551081b6, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Thu Apr 25 00:26:00 CST 2013, time=2013-04-25, status=1, ipAttribution=)]
    2013-04-25 bioon6

相关资讯

MedPage:加拿大新指南称糖尿病患者40岁时应该使用他汀类药物

根据加拿大最新指导原则,所有糖尿病患者到40岁时应该开始服用他汀类药物,55岁时服用降血压药物,尽管他们在当时没有其它危险因素。 准则委员会主席、多伦多圣迈克尔医院的Alice Cheng博士说,该指导原则也建议那些年龄30岁以上、患糖尿病至少15年的患者也应该开始使用他汀类药物。 Cheng对MedPage Today说,“在加拿大,仅13%的2型糖尿病患者在血糖、血压和LDL胆固醇控制3个

Diabetes Care:肌肉心肺耐力可测胰岛素抵抗

    《糖尿病护理》(Diabetes Care)杂志2013年4月11日在线发表的一项研究指出,对于青年人群胰岛素抵抗与β细胞功能受损的一级预防,肌肉耐力与心肺耐力(CRF)水平或可作为靶向观测指标。   研究者在317例来自欧洲青年心脏研究(European Youth Heart Study)的受试者中,分别评估其腹、背部等长肌肉力量以

JACC:高剂量他汀治疗存在两难抉择

近日《美国心脏病学会杂志》在线发表的一项研究表明,对于糖尿病风险较高的患者[合并2-4个新发糖尿病(NOD)危险因素],每日服用高剂量阿托伐他汀(80mg/日)时或应考虑降低剂量。   研究显示,对于NOD风险较低者(合并0-1个NOD危险因素),每日服用高剂量阿托伐他汀(80mg/日)不会增加NOD发生率。然而若患者糖尿病发生风险较高,合并了2-4个NOD危险因素,则每日服用高剂量比低剂量(1

Diabetes Care:Canagliflozin降糖效果不劣于西格列汀

    对于二甲双胍联合磺脲类药物血糖控制不佳的2型糖尿病患者,canagliflozin [一种钠—葡萄糖协同转运子2(SGLT2)抑制剂] 或可成为糖尿病治疗的又一选择。在一项3期临床试验中canagliflozin显示出降糖与体重改善方面相对于西格列汀的优势,但研究同时指出服用canagliflozin的女性患者需注意生殖器真菌感染风险。该研究2013年4月5

Diabetes Care:甘精胰岛素轻度降低动脉粥样硬化风险

    对于心血管疾病患者和/或糖代谢障碍伴心血管事件风险者,甘精胰岛素治疗可使患者血糖水平恢复正常,并轻度延缓颈动脉内膜中层厚度(CIMT)增加,而每日补充n-3多不饱和脂肪酸(n-3FA)则无此效果。2013年4月5日在线发表于《糖尿病护理》的一项研究得出上述结论。   研究采用随机多中心2 × 2析因设计,共纳入1184例罹患心血管疾病或存在心血管风险的患者,所有患者均伴发空腹

胰腺α-细胞研究全新成果汇总

    长期以来,胰岛β-细胞和胰岛素一直是糖代谢平衡调节和糖尿病发病与防治研究的“主角”。近年来由于细胞生物学和分子生物学的发展,提出胰腺α-细 胞在β-细胞的生长和胰岛素的分泌调节中,可能起着十分重要的作用。α-细胞可以产生和分泌两种不同的激素—Glucagon和GLP-1,前者可以抑制 β-细胞的生长和调节胰岛素分泌,升高血糖;后者则可促进β-细胞的增殖、存